The BLA for tabelecleucel has been granted priority review for the treatment of patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease.
Study Finds Unique Pattern of Blood Clots in Sickle Cell Trait but Low Overall Clot Risk
Despite significant improvements in the perception of biomarker testing, substantial barriers to implementation may persist globally, according to findings presented at the International Association f…
Physicians @OSUCCC_James are pioneering telehealth to give more patients access to lifesaving clinical trials.
Efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
PURPOSE We aim to determine the effectiveness of adding electroacupuncture to standard triple antiemetic therapy for treating chemotherapy-induced nausea and vomiting (CINV). METHODS From March…
The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.
PURPOSE Chronic lymphocytic leukemia (CLL)-phenotype monoclonal B-cell lymphocytosis (MBL) is a premalignant condition that is roughly 500-fold more common than CLL. It is unknown whether…
Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.
In this issue of Blood Advances, Shapiro et al1 report the results of a retrospective study evaluating the use of a CD34+ selected stem cell boost…
Ifinatamab deruxtecan has demonstrated antitumor activity as second-line or later therapy in patients with ES-SCLC.
